Press releases
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
- Revance Announces Proposed Public Offering of Common Stock
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
- Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
- Revance to Participate in Upcoming Investor Conferences
- Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
- Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.20 |
---|---|
High | 3.20 |
Low | 3.20 |
Bid | 3.06 |
Offer | 3.08 |
Previous close | 3.30 |
Average volume | 33.33 |
---|---|
Shares outstanding | 104.22m |
Free float | 95.39m |
P/E (TTM) | -- |
Market cap | 372.05m USD |
EPS (TTM) | -3.81 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 07:11 BST.
More ▼